Skip to main navigation
Skip to search
Skip to main content
Bar-Ilan University Home
Help & FAQ
Link opens in a new tab
Search content at Bar-Ilan University
Home
Researchers
Organisations
Research output
Prizes
Student theses
Courses
Activities
Projects
Press/Media
Datasets
Equipment
Lamivudine treatment for acute severe hepatitis B: A pilot study
H. Schmilovitz-Weiss
, Ziv Ben-Ari
, E. Sikuler
, E. Zuckerman
, W. Sbeit
, Z. Ackerman
, R. Safadi
, Y. Lurie
, G. Rosner
, R. Tur-Kaspa
, R. Reshef
Rabin Medical Center Israel
Tel Aviv University
Soroka Medical Center
Bnai-Zion Medical Center
Western Galilee Medical Center of Nahariya
Hadassah University Medical Centre
Tel Aviv Sourasky Medical Center
Research output
:
Contribution to journal
›
Article
›
peer-review
85
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Lamivudine treatment for acute severe hepatitis B: A pilot study'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Acute Disease
14%
Acute Hepatitis B
14%
Acute Hepatitis B Virus Infection
14%
Acute Severe
100%
Alanine Aminotransferase
14%
Biochemical Response
14%
Chronic Hepatitis
14%
Clinical Response
14%
Coagulopathy
28%
Days of Treatment
14%
De Novo Hepatitis
14%
Encephalopathy
28%
Fulminant Hepatitis
28%
HBsAb
14%
HBV Infection
28%
Hepatitis B e Antigen (HBeAg)
14%
Hepatitis B Surface Antigen (HBsAg)
14%
Hepatitis B Virus
14%
Hepatitis B Virus DNA
28%
Hepatocytes
14%
Immunocompetent Adult
14%
Immunocompromised Patients
28%
Lamivudine
100%
Liver Enzyme Activity
14%
Liver Transplantation
14%
Lysis
14%
Patient Selection
14%
Polymerase Chain Reaction
14%
Protective Titer
14%
Serological Response
14%
Serum Hepatitis
14%
Serum Liver Enzymes
14%
Severe Acute
14%
Severe Hepatitis B
100%
Total Bilirubin
14%
Vascular Complications
14%
Virological Response
14%
Well Tolerated
14%
Medicine and Dentistry
Acute Disease
14%
Acute Hepatitis B
28%
Alanine Aminotransferase
14%
Bilirubin
14%
Brain Disease
28%
Chronic Hepatitis
14%
Coagulopathy
28%
Hepatitis B
100%
Hepatitis B Antibody
14%
Hepatitis B Antigen
14%
Hepatitis B Virus
42%
Hepatitis B(e) Antibody
14%
Hepatitis B(e) Antigen
14%
Hepatocyte
14%
Infection
14%
Lamivudine
100%
Liver Enzyme
14%
Liver Transplantation
14%
Polymerase Chain Reaction
14%
Prospective Study
14%
Virus DNA
28%